新生児発作治療薬の世界市場 – 業界動向と2029年までの予測

Request for TOC TOC のリクエスト Speak to Analyst アナリストに相談する Buy Now今すぐ購入 Inquire Before Buying 事前に問い合わせる Free Sample Report 無料サンプルレポート

新生児発作治療薬の世界市場 – 業界動向と2029年までの予測

  • Pharmaceutical
  • Upcoming Report
  • May 2022
  • Global
  • 350 ページ
  • テーブル数: 220
  • 図の数: 60

新生児発作治療薬の世界市場

Market Size in USD Billion

CAGR :  % Diagram

Diagram 予測期間
2022 –2029
Diagram 市場規模(基準年)
USD 222.50 Million
Diagram Market Size (Forecast Year)
USD 290.73 Million
Diagram CAGR
%
Diagram 主要市場プレーヤー
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

新生児発作治療薬の世界市場、タイプ別(強直発作、間代性およびミオクロニー性発作、非発作性反復行動)、薬剤別(ジランチン、フェノバルビタール、その他)、投与量別(錠剤、注射剤、その他)、投与経路別(経口、非経口、その他)、エンドユーザー別(病院、専門クリニック、在宅ケア、その他)、流通チャネル別(病院薬局、小売薬局、オンライン薬局、その他)– 2029年までの業界動向と予測

新生児発作治療薬市場

市場分析と規模

さまざまな形態のてんかんを患うあらゆる年齢の子供に対する適切な薬の使用法を決定するのに役立つ証拠が限られているため、医師はてんかんを患う子供の治療中に特有の問題に直面します。しかし、生後 1 年以内に起こる発作性疾患である新生児発作および乳児けいれんの治療に抗てんかん薬 (AED) をどのように使用できるかについての理解が最近進展しています。これらの疾患の治療における AED の有効性は議論の的となっており、各子供のこれらの疾患の運命を予測することは困難であるため、どのような進歩も歓迎されます。

Data Bridge Market Research の分析によると、新生児発作治療薬市場は 2021 年に 2 億 2,250 万米ドルと評価され、2029 年には 2 億 9,073 万米ドルに達し、2022 年から 2029 年の予測期間中に 3.40% の CAGR を記録すると予想されています。Data Bridge Market Research チームがまとめた市場レポートには、詳細な専門家の分析、患者の疫学、パイプライン分析、価格分析、規制の枠組みが含まれています。

レポートの範囲と市場セグメンテーション

レポートメトリック

詳細

予測期間

2022年から2029年

基準年

2021

歴史的な年

2020 (2019 - 2014 にカスタマイズ可能)

定量単位

売上高(百万米ドル)、販売数量(個数)、価格(米ドル)

対象セグメント

タイプ(強直発作、間代性およびミオクロニー性発作、非発作性反復行動)、薬剤(ジランチン、フェノバルビタール、その他)、用量(錠剤、注射剤、その他)、投与経路(経口、非経口、その他)、エンドユーザー(病院、専門クリニック、在宅ケア、その他)、流通チャネル(病院薬局、小売薬局、オンライン薬局、その他)

対象国

北米では米国、カナダ、メキシコ、ヨーロッパではドイツ、フランス、英国、オランダ、スイス、ベルギー、ロシア、イタリア、スペイン、トルコ、その他のヨーロッパ、ヨーロッパでは中国、日本、インド、韓国、シンガポール、マレーシア、オーストラリア、タイ、インドネシア、フィリピン、アジア太平洋地域 (APAC) ではその他のアジア太平洋地域 (APAC)、中東およびアフリカ (MEA) の一部としてサウジアラビア、UAE、南アフリカ、エジプト、イスラエル、中東およびアフリカ (MEA) の一部としてその他の中東およびアフリカ (MEA)、南米の一部としてブラジル、アルゼンチン、その他の南米

対象となる市場プレーヤー

Merck KGaA (Germany), Eisai Co., Ltd. (Japan), AstraZeneca (UK), Sanofi (France), Novartis AG (Switzerland), Abbott (US), F. Hoffmann-La Roche Ltd. (Switzerland), Teva Pharmaceutical Industries Ltd. (Ireland), Pfizer Inc. (US), GlaxoSmithKline plc (UK), WOCKHARDT (Mumbai), Novo Nordisk A/S (Denmark), Glenmark Pharmaceuticals Limited (India), Cipla Inc. (US), Bausch Health Companies Inc. (Canada), Otsuka America Pharmaceutical, Inc. (US), Johnson & Johnson Private Limited (US), Takeda Pharmaceutical Company Limited (Japan), Sumitomo Corporation (Japan), Biocon (India)

Market Opportunities

  • Increase in the number of emerging markets
  • Increase in the number of research and development activities
  • Surging drug approvals and launches

Market Definition

Seizures in neonates are aberrant electrical discharges in the central nervous system that typically appear as stereotyped muscle activity or autonomic abnormalities. Electroencephalography confirms the diagnosis, and further testing for reasons is recommended. Treatment is determined by the underlying cause. Seizures affect up to 1.4 percent of full-term new-borns and 20% of premature infants. Seizures could be a sign of a significant neonatal condition that has to be evaluated right away. The lack of myelination and insufficient creation of dendrites and synapses in neonates prevents generalization of electrical activity, hence most neonatal seizures are focal.

Neonatal Seizures Drugs Market Dynamics

Drivers

  • Increasing prevalence of hypoxia-ischemia

The rising prevalence of hypoxia-ischemia is anticipated to influence the neonatal seizures drugs? market's growth. The most prevalent cause of neonatal seizures is hypoxia-ischemia, which can occur before, during, or after delivery. Seizures of this nature can be severe and difficult to treat, but they usually subside after 3 to 4 days. Seizures may be less severe when new-born hypoxia is treated with therapeutic hypothermia (typically whole-body chilling), although they may recur upon rewarming.

  • Rising incidences of neonatal infections

The increasing incidences of neonatal infections is expected to flourish the market's growth rate during the forecast period of 2022-2029. Seizures can occur as a result of neonatal infections including meningitis and sepsis; in these cases, seizures are usually accompanied by other symptoms and signs. In neonates, group B streptococci and gram-negative bacteria are the most common causes of infection. Seizures can also be caused by encephalitis caused by the cytomegalovirus, herpes simplex virus, rubella virus, Treponema pallidum, Toxoplasma gondii, or Zika virus.

Furthermore, rising initiatives by public and private organizations to spread awareness will expand the neonatal seizures drugs? market. Additionally, rising healthcare expenditure and changing lifestyle of people will result in the expansion of neonatal seizures drugs? market. Along with this, rising prevalence rate of chronic disease such as thyroid, diabetes, and kidney disease, and favourable reimbursement policies will enhance the market's growth rate.

Opportunities

  • Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the neonatal seizures drugs? market growth. Along with this, rising drug approvals and launches will further propel the market's growth rate.

Moreover, rising investment for the development of advanced technologies and an increase in the number of emerging markets will further provide beneficial opportunities for the growth of neonatal seizures drugs during the forecast period.

Restraints/Challenges

On the other hand, the high cost associated with the drug development and distribution? will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the neonatal seizures drugs? market. Additionally, the side effects of neonatal seizures drugs? will act as market restrain and further impede the market's growth rate during the forecast period of 2022-2029.

This neonatal seizures drugs? market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the neonatal seizures drugs? market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Seizures in new-borns are a common neurological emergency. In terms new-borns, the incidence has been reported to range from 1 to 5.5 per 1000 live births, with greater rates recorded in preterm infants. In the United States, the incidence is estimated to be between 80 and 120 instances per 100,000 new-borns per year.

Neonatal seizures drugs? market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Neonatal Seizures Drugs Market

Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. This can be ascribed to severe disruptions in their respective manufacturing and supply-chain operations, resulting from multiple precautionary lockdowns and other limitations imposed by governments all over the world. The neonatal seizures drugs market was no exception. Furthermore, consumer preferences has decreased as people are now much more concentrated on removing non-essential expenses from their budgets as the wider economic situation of most people has been adversely impacted by this outbreak. Over the forecast period, the aforementioned factors were likely to have a negative impact on the neonatal seizures drugs market's revenue trajectory. However, now that COVID-19 vaccines are readily available, numerous authorities are trying to assure that life-saving medications and vaccines are supplied without interruption. As a result, the market is projected to stabilize in the future.

Global Neonatal Seizures Drugs Market Scope

The neonatal seizures drugs? market is segmented on the basis of type, drug, dosage, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

  • Tonic Seizures
  • Clonic and Myoclonic Seizures
  • Non Paroxysmal Repetitive Behaviours

Drug

  • Dilantin
  • Phenobarbital
  • Other

Dosage

  • Injection
  • Tablets
  • Others

Route of Administration

  • Oral
  • Parenteral
  • Others

 End-Users

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

Neonatal Seizures Drugs Market Regional Analysis/Insights

The neonatal seizures drugs? market is analysed and market size insights and trends are provided by country, type, drug, dosage, route of administration, end-users and distribution channel as referenced above.

The countries covered in the neonatal seizures drugs? market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the neonatal seizures drugs? market because of the rising level of investment on research and development activities in this region. Additionally, the growing presence of major key players and well-established healthcare infrastructure will further propel themarket's growth rate in this region.

Asia-Pacific are expected to grow during the forecast period of 2022-2029 due to rising healthcare expenditure and improvements in healthcare infrastructure in this region. Also, surging prevalence of kidney diseases, thyroid and liver disorders and the number of generic medications will further propel the market's growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Neonatal Seizures Drugs Market Share Analysis

The neonatal seizures drugs? market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to neonatal seizures drugs? market.

Some of the major players operating in the neonatal seizures drugs? market are:

  • Merck KGaA (Germany)
  • Eisai Co., Ltd. (Japan)
  • AstraZeneca (UK)
  • Sanofi (France)
  • Novartis AG (Switzerland)
  • Abbott (US)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Teva Pharmaceutical Industries Ltd. (Ireland)
  • Pfizer Inc. (US)
  • GlaxoSmithKline plc (UK)
  • WOCKHARDT (Mumbai)
  • Novo Nordisk A/S (Denmark)
  • Glenmark Pharmaceuticals Limited (India)
  • Cipla Inc. (US)
  • Bausch Health Companies Inc. (Canada)
  • 大塚アメリカ製薬株式会社(米国)
  • ジョンソン・エンド・ジョンソン プライベート・リミテッド(米国)
  • 武田薬品工業株式会社(日本)
  • 住友商事(日本)
  • バイオコン(インド)  


SKU-

世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする

  • インタラクティブなデータ分析ダッシュボード
  • 成長の可能性が高い機会のための企業分析ダッシュボード
  • カスタマイズとクエリのためのリサーチアナリストアクセス
  • インタラクティブなダッシュボードによる競合分析
  • 最新ニュース、更新情報、トレンド分析
  • 包括的な競合追跡のためのベンチマーク分析のパワーを活用
デモのリクエスト

調査方法

データ収集と基準年分析は、大規模なサンプル サイズのデータ​​収集モジュールを使用して行われます。この段階では、さまざまなソースと戦略を通じて市場情報または関連データを取得します。過去に取得したすべてのデータを事前に調査および計画することも含まれます。また、さまざまな情報ソース間で見られる情報の不一致の調査も含まれます。市場データは、市場統計モデルと一貫性モデルを使用して分析および推定されます。また、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。詳細については、アナリストへの電話をリクエストするか、お問い合わせをドロップダウンしてください。

DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数が市場に与える影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、特許分析、価格分析、企業市場シェア分析、測定基準、グローバルと地域、ベンダー シェア分析が含まれます。調査方法について詳しくは、お問い合わせフォームから当社の業界専門家にご相談ください。

カスタマイズ可能

Data Bridge Market Research は、高度な形成的調査のリーダーです。当社は、既存および新規のお客様に、お客様の目標に合致し、それに適したデータと分析を提供することに誇りを持っています。レポートは、対象ブランドの価格動向分析、追加国の市場理解 (国のリストをお問い合わせください)、臨床試験結果データ、文献レビュー、リファービッシュ市場および製品ベース分析を含めるようにカスタマイズできます。対象競合他社の市場分析は、技術ベースの分析から市場ポートフォリオ戦略まで分析できます。必要な競合他社のデータを、必要な形式とデータ スタイルでいくつでも追加できます。当社のアナリスト チームは、粗い生の Excel ファイル ピボット テーブル (ファクト ブック) でデータを提供したり、レポートで利用可能なデータ セットからプレゼンテーションを作成するお手伝いをしたりすることもできます。

Frequently Asked Questions

The market value for neonatal seizures drugs market is expected USD 290.73 million by 2029.
The neonatal seizures drugs market is to grow at a CAGR of 3.40% during the forecast period of 2022 to 2029
The major players operating in the Neonatal Seizures Drugs Market are Merck KGaA (Germany), Eisai Co., Ltd. (Japan), AstraZeneca (UK), Sanofi (France), Novartis AG (Switzerland), Abbott (US), F. Hoffmann-La Roche Ltd. (Switzerland), Teva Pharmaceutical Industries Ltd. (Ireland), Pfizer Inc. (US), GlaxoSmithKline plc (UK), WOCKHARDT (Mumbai), Novo Nordisk A/S (Denmark), Glenmark Pharmaceuticals Limited (India), Cipla Inc. (US), Bausch Health Companies Inc. (Canada), Otsuka America Pharmaceutical, Inc. (US), Johnson & Johnson Private Limited (US), Takeda Pharmaceutical Company Limited (Japan), Sumitomo Corporation (Japan), Biocon (India).
The major countries covered in the Neonatal Seizures Drugs Market are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.